RHYTHM Biosciences Ltd (RHY) - Total Assets
Based on the latest financial reports, RHYTHM Biosciences Ltd (RHY) holds total assets worth AU$3.10 Million AUD (≈ $2.19 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See RHY book value for net asset value and shareholders' equity analysis.
RHYTHM Biosciences Ltd - Total Assets Trend (2017–2025)
This chart illustrates how RHYTHM Biosciences Ltd's total assets have evolved over time, based on quarterly financial data.
RHYTHM Biosciences Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
RHYTHM Biosciences Ltd's total assets of AU$3.10 Million consist of 64.0% current assets and 36.0% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 49.3% |
| Accounts Receivable | AU$61.91K | 2.2% |
| Inventory | AU$74.36K | 2.6% |
| Property, Plant & Equipment | AU$171.03K | 6.0% |
| Intangible Assets | AU$318.13K | 11.2% |
| Goodwill | AU$531.02K | 18.8% |
Asset Composition Trend (2017–2025)
This chart illustrates how RHYTHM Biosciences Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see RHY market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: RHYTHM Biosciences Ltd's current assets represent 64.0% of total assets in 2025, a decrease from 96.8% in 2017.
- Cash Position: Cash and equivalents constituted 49.3% of total assets in 2025, down from 96.5% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 29.0% of total assets, an increase from 3.0% in 2017.
- Asset Diversification: The largest asset category is goodwill at 18.8% of total assets.
RHYTHM Biosciences Ltd Competitors by Total Assets
Key competitors of RHYTHM Biosciences Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY
|
USA | $12.17 Billion |
|
INTERGRATED DIA.H DL 025
F:8I8
|
Germany | €6.77 Billion |
|
Immunovia publ AB
ST:IMMNOV
|
Sweden | Skr88.21 Million |
|
IZOTROPIC CORP.
F:1R3
|
Germany | €685.34K |
|
Wellfully Ltd
AU:WFL
|
Australia | AU$3.51 Million |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
RHYTHM Biosciences Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.31 | 4.87 | 9.95 |
| Quick Ratio | 2.23 | 4.79 | 9.95 |
| Cash Ratio | 0.00 | 0.00 | 9.62 |
| Working Capital | AU$1.23 Million | AU$3.84 Million | AU$5.60 Million |
RHYTHM Biosciences Ltd - Advanced Valuation Insights
This section examines the relationship between RHYTHM Biosciences Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 28.31 |
| Latest Market Cap to Assets Ratio | 9.83 |
| Asset Growth Rate (YoY) | 86.5% |
| Total Assets | AU$2.83 Million |
| Market Capitalization | $27.85 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values RHYTHM Biosciences Ltd's assets at a significant premium (9.83x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: RHYTHM Biosciences Ltd's assets grew by 86.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for RHYTHM Biosciences Ltd (2017–2025)
The table below shows the annual total assets of RHYTHM Biosciences Ltd from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$2.83 Million ≈ $2.00 Million |
+86.46% |
| 2024-06-30 | AU$1.52 Million ≈ $1.07 Million |
-80.26% |
| 2023-06-30 | AU$7.70 Million ≈ $5.45 Million |
-8.80% |
| 2022-06-30 | AU$8.44 Million ≈ $5.97 Million |
+174.87% |
| 2021-06-30 | AU$3.07 Million ≈ $2.17 Million |
+16.02% |
| 2020-06-30 | AU$2.65 Million ≈ $1.87 Million |
-57.53% |
| 2019-06-30 | AU$6.23 Million ≈ $4.41 Million |
-26.27% |
| 2018-06-30 | AU$8.45 Million ≈ $5.98 Million |
+445.29% |
| 2017-06-30 | AU$1.55 Million ≈ $1.10 Million |
-- |
About RHYTHM Biosciences Ltd
Rhythm Biosciences Limited, a medical diagnostics company, provides blood tests for the detection of cancers in Australia and the United States. It offers ColoSTAT, a blood test for the early detection of colorectal cancer; and geneType, a personalized predictive test for predicting risk of chronic disease development. The company was incorporated in 2017 and is headquartered in Parkville, Austra… Read more